Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: SkyQuest | PRODUCT CODE: 2003569

Cover Image

PUBLISHER: SkyQuest | PRODUCT CODE: 2003569

Graves Disease Treatment Market Size, Share, and Growth Analysis, By Therapy Type, By Surgical Intervention, By Clinical Manifestation, By End-User, By Region - Industry Forecast 2026-2033

PUBLISHED:
PAGES: 157 Pages
DELIVERY TIME: 3-5 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5300
PDF & Excel (Multiple User License)
USD 6200
PDF & Excel (Enterprise License)
USD 7100

Add to Cart

Global Graves Disease Treatment Market size was valued at USD 2.5 Billion in 2024 and is poised to grow from USD 2.64 Billion in 2025 to USD 4.05 Billion by 2033, growing at a CAGR of 5.5% during the forecast period (2026-2033).

The global Graves disease treatment market is experiencing significant growth driven by increased awareness and the diagnosis of autoimmune thyroid disorders, alongside advancements in therapy. This sector includes a range of treatment options, such as antithyroid medications, radioactive iodine ablation, and innovative biologic therapies, addressing the severe consequences of uncontrolled hyperthyroidism, including morbidity and vision loss. Historical treatment methods are evolving due to recent clinical innovations and regulatory approvals that enhance care pathways. The market is further stimulated by therapeutic diversification and heightened accessibility to advanced diagnostic technologies. Additionally, AI integration in diagnosis and treatment facilitates timely interventions, improves patient outcomes, and allows for greater customization of care, particularly in emerging markets, creating lucrative opportunities for pharmaceutical and diagnostic companies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Graves Disease Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Graves Disease Treatment Market Segments Analysis

Global graves disease treatment market is segmented by therapy type, surgical intervention, clinical manifestation, end-user and region. Based on therapy type, the market is segmented into Antithyroid Drugs, Radioactive Iodine Therapy, Beta-Blockers and Targeted Biologics. Based on surgical intervention, the market is segmented into Total/Partial Thyroidectomy and Orbital Decompression. Based on clinical manifestation, the market is segmented into Hyperthyroidism Focus, Graves' Ophthalmopathy and Graves' Dermopathy. Based on end-user, the market is segmented into Endocrine Specialty Clinics, Hospitals & Tertiary Care Centers and Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Graves Disease Treatment Market

The rising global incidence of Graves disease has led to a growing number of patients in need of effective treatment solutions, compelling healthcare providers to focus on improved diagnostic and management strategies. As the patient population expands, so does the demand for both established and innovative therapies, which in turn drives investment in clinical research and the enhancement of healthcare infrastructure. This persistent need from patients encourages pharmaceutical companies to refine their product formulations and delivery systems, while clinicians adopt more comprehensive treatment guidelines. Overall, the increased prevalence actively propels market growth, facilitating consistent product utilization and long-term strategic planning among industry stakeholders.

Restraints in the Global Graves Disease Treatment Market

The Global Graves Disease Treatment market faces significant challenges due to high costs linked to advanced therapies and specialized procedures, which can restrict patient access and reduce reimbursement support from payers. These affordability concerns prompt healthcare providers and institutions to favor established, cost-effective treatments over newer, potentially more beneficial options. Consequently, cost sensitivity affects formulary choices and procurement strategies, hindering the adoption of innovative treatments. This economic pressure serves as a notable barrier to the wider acceptance and growth of the treatment market, ultimately impacting the development and integration of new therapeutic solutions in clinical practice.

Market Trends of the Global Graves Disease Treatment Market

The Global Graves Disease Treatment market is witnessing a notable shift towards personalized care models, where healthcare providers are increasingly customizing treatment plans to fit individual patient profiles. This trend emphasizes a multidisciplinary approach, engaging endocrinologists, ophthalmologists, and mental health specialists to enhance treatment adherence and overall quality of life. Innovative protocols are focusing on individualized dosing strategies, fostering shared decision-making, and prioritizing patient education. Additionally, manufacturers are responding with targeted therapeutic options and companion diagnostics, while payer conversations are steering towards value-based outcomes that align therapy selection with long-term patient-centered goals, creating a more integrated healthcare ecosystem.

Product Code: SQMIG35I2566

Table of Contents

Introduction

  • Objectives of the Study
  • Market Definition & Scope

Research Methodology

  • Research Process
  • Secondary & Primary Data Methods
  • Market Size Estimation Methods

Executive Summary

  • Global Market Outlook
  • Key Market Highlights
  • Segmental Overview
  • Competition Overview

Market Dynamics & Outlook

  • Macro-Economic Indicators
  • Drivers & Opportunities
  • Restraints & Challenges
  • Supply Side Trends
  • Demand Side Trends
  • Porters Analysis & Impact
    • Competitive Rivalry
    • Threat of Substitute
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Key Success Factors
  • Market Impacting Factors
  • Top Investment Pockets
  • Ecosystem Mapping
  • Market Attractiveness Index 2025
  • PESTEL Analysis
  • Regulatory Landscape

Global Graves Disease Treatment Market Size by Therapy Type & CAGR (2026-2033)

  • Market Overview
  • Antithyroid Drugs
  • Radioactive Iodine Therapy
  • Beta-Blockers
  • Targeted Biologics

Global Graves Disease Treatment Market Size by Surgical Intervention & CAGR (2026-2033)

  • Market Overview
  • Total/Partial Thyroidectomy
  • Orbital Decompression

Global Graves Disease Treatment Market Size by Clinical Manifestation & CAGR (2026-2033)

  • Market Overview
  • Hyperthyroidism Focus
  • Graves' Ophthalmopathy
  • Graves' Dermopathy

Global Graves Disease Treatment Market Size by End-User & CAGR (2026-2033)

  • Market Overview
  • Endocrine Specialty Clinics
  • Hospitals & Tertiary Care Centers
  • Retail Pharmacies

Global Graves Disease Treatment Market Size & CAGR (2026-2033)

  • North America (Therapy Type, Surgical Intervention, Clinical Manifestation, End-User)
    • US
    • Canada
  • Europe (Therapy Type, Surgical Intervention, Clinical Manifestation, End-User)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Therapy Type, Surgical Intervention, Clinical Manifestation, End-User)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Therapy Type, Surgical Intervention, Clinical Manifestation, End-User)
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Therapy Type, Surgical Intervention, Clinical Manifestation, End-User)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2025
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2025
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

  • Genzyme Corporation
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly and Company
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Amgen Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novo Nordisk A/S
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol-Myers Squibb Company
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline plc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceutical Company Limited
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Medtronic plc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Boehringer Ingelheim
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Astellas Pharma Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ipsen S.A.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!